UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2018

Commission File Number 000-29338

CORREVIO PHARMA CORP.

(Translation of registrant's name into English)

1441 Creekside Drive, 6th Floor

Vancouver, British Columbia, Canada V6J 4S7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F   x       Form 40-F    ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit	Description
99.1	Press Release, dated July 10, 2018, Correvio Announces At the Market Offering
99.2	At Market Issuance Sales Agreement, dated July 10, 2018, between Correvio Pharma Corp. and B. Riley FBR, Inc.

Exhibit 99.2 of this report on Form 6-K is incorporated by reference into the Company’s registration statement on Form F-10 (File No. 333-225852).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CORREVIO PHARMA CORP.

(Registrant)

Date:	July 10, 2018	By:	/s/ Justin Renz
			Name:	Justin Renz
			Title:	Chief Financial Officer